These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28018697)

  • 1. Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine.
    Miller CW; Gallagher KE
    Case Rep Psychiatry; 2016; 2016():5472492. PubMed ID: 28018697
    [No Abstract]   [Full Text] [Related]  

  • 2. Kleptomania Induced by Venlafaxine.
    Sakurada K; Nibuya M; Yamada K; Nakagawa S; Suzuki E
    Case Rep Psychiatry; 2021; 2021():8470045. PubMed ID: 34540303
    [No Abstract]   [Full Text] [Related]  

  • 3. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impulse Control and Related Disorders in Parkinson's Disease.
    Weintraub D; Claassen DO
    Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
    Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential efficacy of serotonin noradrenaline reuptake inhibitor duloxetine in dropped head syndrome: A case report and review of the literature.
    Funao H; Isogai N; Ishii K
    Heliyon; 2020 Aug; 6(8):e04774. PubMed ID: 32885085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
    Chalon SA; Granier LA; Vandenhende FR; Bieck PR; Bymaster FP; Joliat MJ; Hirth C; Potter WZ
    Neuropsychopharmacology; 2003 Sep; 28(9):1685-93. PubMed ID: 12784100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice.
    Fuller RW; Hemrick-Luecke SK; Snoddy HD
    J Pharmacol Exp Ther; 1994 Apr; 269(1):132-6. PubMed ID: 7513356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probable Association of an Attack of Bilateral Acute Angle-Closure Glaucoma With Duloxetine.
    Shifera AS; Leoncavallo A; Sherwood M
    Ann Pharmacother; 2014 Jul; 48(7):936-939. PubMed ID: 24732786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysosmia and dysgeusia associated with duloxetine.
    Yoshida K; Fukuchi T; Sugawara H
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29170185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noradrenaline reuptake inhibition increases control of impulsive action by activating D
    Sasamori H; Ohmura Y; Yoshida T; Yoshioka M
    Eur J Pharmacol; 2019 Feb; 844():17-25. PubMed ID: 30503361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
    Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
    Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP).
    Sharma A; Goyal V; Behari M; Srivastva A; Shukla G; Vibha D
    Ann Indian Acad Neurol; 2015; 18(1):49-59. PubMed ID: 25745311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nigrostriatal and Mesolimbic D
    Stark AJ; Smith CT; Lin YC; Petersen KJ; Trujillo P; van Wouwe NC; Kang H; Donahue MJ; Kessler RM; Zald DH; Claassen DO
    J Neurosci; 2018 Mar; 38(13):3230-3239. PubMed ID: 29483278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The many different faces of major depression: it is time for personalized medicine.
    Korte SM; Prins J; Krajnc AM; Hendriksen H; Oosting RS; Westphal KG; Korte-Bouws GA; Olivier B
    Eur J Pharmacol; 2015 Apr; 753():88-104. PubMed ID: 25592320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Management of Trigeminal Neuralgia and Comorbid Major Depressive Disorder With Duloxetine.
    Hsu CC; Chang CW; Peng CH; Liang CS
    Ann Pharmacother; 2014 Aug; 48(8):1090-1092. PubMed ID: 24788987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum?
    Nishijima H; Tomiyama M
    Front Neurosci; 2016; 10():575. PubMed ID: 28018168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease.
    Vriend C; Nordbeck AH; Booij J; van der Werf YD; Pattij T; Voorn P; Raijmakers P; Foncke EM; van de Giessen E; Berendse HW; van den Heuvel OA
    Mov Disord; 2014 Jun; 29(7):904-11. PubMed ID: 24832846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.